NASDAQ:ORMP

Oramed Pharmaceuticals Stock Forecast, Price & News

$4.37

-0.09 (-2.02 %)

(As of 01/15/2021 12:00 AM ET)

Add

Compare

Today's Range

$4.34

Now: $4.37▼

$4.56

50-Day Range

$3.23

MA: $4.31▼

$4.64

52-Week Range

$2.40

Now: $4.37▼

$5.71

Volume246,881 shs

Average Volume173,108 shs

Market Capitalization$103.46 million

P/E RatioN/A

Dividend YieldN/A

Beta1.58

Oramed Pharmaceuticals Inc. engages in the research and development of pharmaceutical solutions for the treatment of diabetes and for the use of orally ingestible capsules or pills for delivery of polypeptides. Its proprietary flagship product is the ORMD-0801, an orally ingestible insulin capsule, which completed phase II clinical trials for the treatment of individuals with diabetes. It is also developing ORMD-0901, an oral glucagon-like peptide-1 capsule that has completed phase I clinical trials for the treatment of type 2 diabetes; and a weight loss treatment in the form of an oral leptin capsule. The company was formerly known as Integrated Security Technologies, Inc. and changed its name to Oramed Pharmaceuticals Inc. in April 2006. Oramed Pharmaceuticals Inc. was founded in 2002 and is based in New York, New York.

MarketRank^™

Overall MarketRank^™

1.32 out of 5 stars

Medical Sector

580th out of 1,558 stocks

Pharmaceutical Preparations Industry

296th out of 638 stocks

3.5 Analyst's Opinion

Consensus Rating
Oramed Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $11.17, Oramed Pharmaceuticals has a forecasted upside of 155.5% from its current price of $4.37.
Amount of Analyst Coverage
Oramed Pharmaceuticals has only been the subject of 1 research reports in the past 90 days.

3.1 Community Rank

Outperform Votes
Oramed Pharmaceuticals has received 298 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Oramed Pharmaceuticals has received 184 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Oramed Pharmaceuticals has received 61.83% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Oramed Pharmaceuticals and other stocks. Vote “Outperform” if you believe ORMP will outperform the S&P 500 over the long term. Vote “Underperform” if you believe ORMP will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Oramed Pharmaceuticals does not currently pay a dividend.
Dividend Growth
Oramed Pharmaceuticals does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Oramed Pharmaceuticals insiders have not sold or bought any company stock.
Percentage Held by Insiders
Only 16.10% of the stock of Oramed Pharmaceuticals is held by insiders.
Percentage Held by Institutions
Only 3.99% of the stock of Oramed Pharmaceuticals is held by institutions.

0.0 Earnings and Valuation

Earnings Growth
Earnings for Oramed Pharmaceuticals are expected to decrease in the coming year, from ($0.57) to ($0.70) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Oramed Pharmaceuticals is -13.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Oramed Pharmaceuticals is -13.24, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
Oramed Pharmaceuticals has a P/B Ratio of 3.90. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryN/A

SectorMedical

Current SymbolNASDAQ:ORMP

Previous Symbol

CUSIPN/A

CIK1176309

Webwww.oramed.com

Phone844-967-2633

EmployeesN/A

Debt

Debt-to-Equity RatioN/A

Current Ratio9.99

Quick Ratio9.99

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$2.70 million

Price / Sales38.32

Cash Flow$1.28 per share

Price / Cash Flow3.41

Book Value$1.12 per share

Price / Book3.90

Profitability

EPS (Most Recent Fiscal Year)$0.82

Net Income$-14,350,000.00

Net Margins-230.07%

Return on Equity-28.75%

Return on Assets-17.58%

Miscellaneous

Outstanding Shares23,676,000

Market Cap$103.46 million

Next Earnings Date4/5/2021 (Estimated)

OptionableOptionable

$4.37

-0.09 (-2.02 %)

(As of 01/15/2021 12:00 AM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive ORMP News and Ratings via Email

Sign-up to receive the latest news and ratings for ORMP and its competitors with MarketBeat's FREE daily newsletter.

Oramed Pharmaceuticals (NASDAQ:ORMP) Frequently Asked Questions

How has Oramed Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

Oramed Pharmaceuticals' stock was trading at $3.31 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ORMP stock has increased by 32.0% and is now trading at $4.37.
View which stocks have been most impacted by COVID-19.

Is Oramed Pharmaceuticals a buy right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Oramed Pharmaceuticals in the last twelve months. There are currently 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" Oramed Pharmaceuticals stock.
View analyst ratings for Oramed Pharmaceuticals or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Oramed Pharmaceuticals?

Wall Street analysts have given Oramed Pharmaceuticals a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Oramed Pharmaceuticals wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Oramed Pharmaceuticals' next earnings date?

Oramed Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Monday, April 5th 2021.
View our earnings forecast for Oramed Pharmaceuticals.

How were Oramed Pharmaceuticals' earnings last quarter?

Oramed Pharmaceuticals Inc. (NASDAQ:ORMP) released its quarterly earnings data on Wednesday, January, 13th. The biotechnology company reported ($0.23) EPS for the quarter, missing the Zacks' consensus estimate of ($0.15) by $0.09. Oramed Pharmaceuticals had a negative return on equity of 28.75% and a negative net margin of 230.07%.
View Oramed Pharmaceuticals' earnings history.

What price target have analysts set for ORMP?

3 Wall Street analysts have issued 1-year target prices for Oramed Pharmaceuticals' shares. Their forecasts range from $5.50 to $17.00. On average, they anticipate Oramed Pharmaceuticals' share price to reach $11.17 in the next year. This suggests a possible upside of 155.5% from the stock's current price.
View analysts' price targets for Oramed Pharmaceuticals or view Wall Street analyst' top-rated stocks.

Who are some of Oramed Pharmaceuticals' key competitors?

Some companies that are related to Oramed Pharmaceuticals include TherapeuticsMD (TXMD), ANI Pharmaceuticals (ANIP), BeyondSpring (BYSI), TFF Pharmaceuticals (TFFP), Avadel Pharmaceuticals (AVDL), Marinus Pharmaceuticals (MRNS), Selecta Biosciences (SELB), OrganiGram (OGI), Aeglea BioTherapeutics (AGLE), Cue Biopharma (CUE), Athersys (ATHX), Immunic (IMUX), CytomX Therapeutics (CTMX), Concert Pharmaceuticals (CNCE) and Catalyst Pharmaceuticals (CPRX).
View all of ORMP's competitors.

What other stocks do shareholders of Oramed Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Oramed Pharmaceuticals investors own include TransEnterix (TRXC), Compugen (CGEN), Sarepta Therapeutics (SRPT), Zynerba Pharmaceuticals (ZYNE), Inovio Pharmaceuticals (INO), Sorrento Therapeutics (SRNE), DURECT (DRRX), OPKO Health (OPK), Pluristem Therapeutics (PSTI) and Palatin Technologies (PTN).

Who are Oramed Pharmaceuticals' key executives?

Oramed Pharmaceuticals' management team includes the following people:

Mr. Nadav Kidron, Pres, CEO & Exec. Director (Age 46, Pay $1.2M)
Mr. Avraham Gabay, CFO, Treasurer & Sec. (Age 35, Pay $191.06k)
Mr. Joshua Hexter, Chief Operating & Bus. Officer (Age 50, Pay $267.82k)
Dr. Miriam Kidron, Chief Scientific Officer & Director (Age 80, Pay $389.19k)
Dr. Roy Eldor M.D., Ph.D., Chief Medical Advisor & Member of the Scientific Advisory Board

What is Oramed Pharmaceuticals' stock symbol?

Oramed Pharmaceuticals trades on the NASDAQ under the ticker symbol "ORMP."

How do I buy shares of Oramed Pharmaceuticals?

Shares of ORMP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Oramed Pharmaceuticals' stock price today?

One share of ORMP stock can currently be purchased for approximately $4.37.

How big of a company is Oramed Pharmaceuticals?

Oramed Pharmaceuticals has a market capitalization of $103.46 million and generates $2.70 million in revenue each year. The biotechnology company earns $-14,350,000.00 in net income (profit) each year or $0.82 on an earnings per share basis.

What is Oramed Pharmaceuticals' official website?

The official website for Oramed Pharmaceuticals is www.oramed.com.

How can I contact Oramed Pharmaceuticals?

Oramed Pharmaceuticals' mailing address is 1185 AVENUE SUITE 228, NEW YORK NY, 10036. The biotechnology company can be reached via phone at 844-967-2633 or via email at [email protected]

This page was last updated on 1/17/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here